Global

News Releases

This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

31 March 2017 Jeffrey Modell Foundation to Open the First North African Network for Primary Immunodeficiencies

Like the other 253 sites that comprise the Jeffrey Modell Centers Network, the North African Network will offer advanced diagnostic evaluation to patients with a suspected primary immunodeficiency, a group of over 350 disorders arising from defects in the immune system carried by the genes and characterized by recurring infections that can be persistent, debilitating, chronic and life-threatening.

> Read More
29 March 2017 Patient Advocacy Organizations Continue to Develop Innovative Ways to Advocate for Patients

Patients are the most compelling advocates for access to care, which is why CSL Behring awards Local Empowerment for Advocacy Development (LEAD) grants to support advocacy work of rare disease patient groups. These groups tackle complex legislative and public policy issues and ensure patients’ voices are heard on Capitol Hill and in statehouses across the U.S.

> Read More
22 March 2017 NEJM Publishes Pivotal Data on Preventing HAE Attacks

The New England Journal of Medicine published data from the COMPACT study which demonstrated the safety and efficacy of CSL830 to prevent HAE attacks.

> Read More
01 March 2017 Largest Ever CIDP Clinical Study Completed

Global biotherapeutics leader CSL Behring announced today that it has completed the largest ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, known as PATH (Polyneuropathy And Treatment with Hizentra®).

> Read More
14 February 2017 FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition

Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s clinical efficacy supplement to its Biologics License Application (BLA) for Privigen® [Immune Globulin Intravenous (Human), 10% Liquid], its intravenous immunoglobulin (IVIg).

> Read More
Page 5 of 7 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+